Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun:57:29-36.
doi: 10.1016/j.cct.2017.03.006. Epub 2017 Mar 19.

Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients

L Wenzel  1 , D Mukamel  2 , K Osann  2 , L Havrilesky  3 , L Sparks  4 , J Lipscomb  5 , A A Wright  6 , J Walker  7 , R Alvarez  8 , L Van Le  9 , K Robison  10 , R Bristow  2 , R Morgan  11 , B J Rimel  12 , H Ladd  2 , S Hsieh  2 , A Wahi  2 , D Cohn  13
Affiliations

Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients

L Wenzel et al. Contemp Clin Trials. 2017 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Definition of IP therapy.
Fig. 2.
Fig. 2.
Side effect explanation example.
Fig. 3.
Fig. 3.
Study Design.
Fig. 4.
Fig. 4.
CONSORT diagram.
Fig. 5.
Fig. 5.
PCOA at home.
See this image and copyright information in PMC

References

    1. American Cancer Society, Cancer Facts & Figures 2016, American Cancer Society, Atlanta, 2016.
    1. Alberts DS, et al., Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer, N. Engl. J. Med 335 (26) (1996) 1950–1955. - PubMed
    1. Armstrong DK, et al., Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N. Engl. J. Med 354(1) (2006) 34–43. - PubMed
    1. Markman M, et al., Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group, J. Clin. Oncol 19 (4) (2001) 1001–1007. - PubMed
    1. Walker J, Brady M, DiSilvestro P, A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube and primary peritoneal carcinoma NCI-supplied agent (s): bevacizumab (NSC# 704865, IND# 7921) NCT01167712 a GOG/NRG trial (GOG 252), SGO Annual Meeting, 2016.

Publication types